- Home
- ADPT vs GNTX Comparison
ADPT vs GNTX Comparison
Compare ADPT & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | GNTX |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.0B |
| IPO Year | 2019 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ADPT | GNTX |
|---|---|---|
| Price | $25.90 | $21.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $28.31 | $27.28 |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 11-04-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | $276,976,000.00 | ★ $2,534,268,965.00 |
| Revenue This Year | $5.94 | $5.41 |
| Revenue Next Year | $22.42 | $5.11 |
| P/E Ratio | ★ N/A | $21.11 |
| Revenue Growth | ★ 54.77 | 9.55 |
| 52 Week Low | $12.00 | $20.48 |
| 52 Week High | $30.74 | $26.96 |
Technical Indicators
Market Signals| Indicator | ADPT | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 31.17 |
| Support Level | $23.73 | $20.48 |
| Resistance Level | $26.51 | $22.37 |
| Average True Range (ATR) | 1.43 | 0.42 |
| MACD | -0.37 | -0.08 |
| Stochastic Oscillator | 12.46 | 16.85 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.